Skip to main content
. 2021 Feb 20;160(1):74–84. doi: 10.1016/j.chest.2021.02.024

Table 1.

Concomitant Therapeutic Interventions

Intervention Progesterone Group (n = 18) [No. (%)] Control Group (n = 22) [No. (%)]
Azithromycin 10 (55.6) 10 (45.5)
Remdesivir 9 (50.0) 15 (68.2)
Systemic glucocorticoids 9 (50.0) 15 (68.2)
 Dexamethasone 7 (38.9) 10 (45.5)
Tocilizumab 1 (5.6) 4 (18.2)
Convalescent plasma 0 (0.0) 2 (9.1)
Hydroxychloroquine 0 (0.0) 1 (4.5)